<DOC>
	<DOCNO>NCT00560352</DOCNO>
	<brief_summary>The purpose study determine safety tolerability dasatinib bortezomib treatment relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Safety Study Dasatinib With Bortezomib ( VelcadeÂ® ) Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key Confirmed diagnosis multiple myeloma measurable disease Evidence relapse refractory disease least 2 prior therapy multiple myeloma Eastern Cooperative Oncology Group Performance Status 0 2 Last treatment multiple myeloma within 21 day prior study treatment initiation Bone marrow transplant within 3 month prior study treatment initiation Required baseline hematology chemistry parameter . Key Clinically significant cardiac disease ( New York Heart Association Class III IV ) Abnormal QT interval correct heart rate use Fridericia 's formula prolong ( &gt; 450 msec ) electrolytes correct baseline electrocardiogram Malabsorption syndrome uncontrolled gastrointestinal toxicity Dementia , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation Clinically significant pleural effusion previous 12 month current ascites Clinically significant coagulation platelet function disorder Intolerance dasatinib and/or bortezomib Acute diffuse infiltrative pulmonary disease Prior concurrent malignancy , except adequately treat basal cell squamous cell skin cancer , adequately treated Stage I II cancer currently complete remission , cervical carcinoma situ , cancer participant diseasefree 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>